Yes, I am also curious to hear more clarification of this "clinical validation". One thing to note is that this is in the late breaking abstract category. Whereas regular abstracts had a submission deadline of November 17th, 2016, the late breaking abstracts had a January 12th, 2017 submission  deadline. Notification of late breaking abstract acceptance was just sent out February 15th. So this is very recent stuff, and this abstract presentation has the potential (no guarantee) to reveal the most data from the ZEN-3694 trial to date including stuff we've never seen before that may attest to the efficacy of ZEN-3694. Full abstract will be released March 31st.